| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| October 28th, 2005 | 33 | No |
Popular Name: Ursolic acid Ursolic acid
(3beta)-3-hydroxyurs-12-en-28-oic acid; Micromerol; Ursolic acid; malol; prunol; urson
(3beta)-3-hydroxyurs-12-en-28-oic acid; Ursolic acid; malol; prunol; urson
3beta-hydroxyurs-12-en-28-oic acid
77-52-1; Prestwick_355; Ursolic acid
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | 6.79 | 12.05 | -49.78 | 1 | 3 | -1 | 60 | 455.703 | 1 | ↓ |
| Lo Low (pH 4.5-6) | 6.79 | 10.29 | -5.45 | 2 | 3 | 0 | 58 | 456.711 | 1 | ↓ |
| Note Type | Comments | Provided By |
|---|---|---|
| M.P | 280.7-281C | Indofine Natural Products |
| Mp [°C] | 283 - 285 | Acros Organics |
| M.P | 292 °C | Indofine Natural Products |
| Therapy | diuretic, antineoplastic, antiulcer | SMDC MicroSource |
| PUBCHEM_PATENT_ID | EP0081599A1; EP0093520A1; EP0100516A2; EP0147331A2; EP0223245A2; EP0246194A2; EP0246194B1; EP0515159B1; EP0540106A1; EP0555484A1; EP0555484B1; EP0575496A1; EP0575496B1; EP0717613A1; EP0717613B1; EP0774255A1; EP0786934A2; EP0786934B1; EP0832652A1; EP085388 | IBM Patent Data |
| Patent Database Links | EP1674090; EP1726309; EP1980569; US2007184133; US2007184137; US2007189984; US2007203240; US2007218146; US2007231418; US2007243147; US2007254021; WO2006078754; WO2007106049; WO2007121352; WO2007126221; WO2007134003 | ChEBI |
| S phrase | S24/25: Avoid contact with skin and eyes. | Acros Organics |
| SOLUBILITY | Soluble in acetone | Indofine Natural Products |
| APPEARANCE | White powder | Indofine Natural Products |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| DHI1-2-E | 11-beta-hydroxysteroid Dehydrogenase 1 (cluster #2 Of 3), Eukaryotic | Eukaryotes | 1900 | 0.24 | Binding ≤ 10μM |
| DPOLB-2-E | DNA Polymerase Beta (cluster #2 Of 3), Eukaryotic | Eukaryotes | 8500 | 0.22 | Binding ≤ 10μM |
| PA21B-3-E | Phospholipase A2 Group 1B (cluster #3 Of 3), Eukaryotic | Eukaryotes | 2900 | 0.23 | Binding ≤ 10μM |
| PA2A-1-E | Phospholipase A2 Isozyme PLA-A (cluster #1 Of 2), Eukaryotic | Eukaryotes | 2500 | 0.24 | Binding ≤ 10μM |
| PA2GA-3-E | Phospholipase A2, Membrane Associated (cluster #3 Of 3), Eukaryotic | Eukaryotes | 3 | 0.36 | Binding ≤ 10μM |
| PA2GD-2-E | Group IID Secretory Phospholipase A2 (cluster #2 Of 3), Eukaryotic | Eukaryotes | 2500 | 0.24 | Binding ≤ 10μM |
| PA2GE-2-E | Group IIE Secretory Phospholipase A2 (cluster #2 Of 2), Eukaryotic | Eukaryotes | 3 | 0.36 | Binding ≤ 10μM |
| PA2GF-2-E | Group IIF Secretory Phospholipase A2 (cluster #2 Of 2), Eukaryotic | Eukaryotes | 3 | 0.36 | Binding ≤ 10μM |
| PTN1-3-E | Protein-tyrosine Phosphatase 1B (cluster #3 Of 4), Eukaryotic | Eukaryotes | 3900 | 0.23 | Binding ≤ 10μM |
| PTN2-2-E | T-cell Protein-tyrosine Phosphatase (cluster #2 Of 3), Eukaryotic | Eukaryotes | 6700 | 0.22 | Binding ≤ 10μM |
| PYGM-1-E | Muscle Glycogen Phosphorylase (cluster #1 Of 4), Eukaryotic | Eukaryotes | 9000 | 0.21 | Binding ≤ 10μM |
| Q7T3S7-1-E | Phospholipase A2 (cluster #1 Of 2), Eukaryotic | Eukaryotes | 2500 | 0.24 | Binding ≤ 10μM |
| GPBAR-2-E | G-protein Coupled Bile Acid Receptor 1 (cluster #2 Of 2), Eukaryotic | Eukaryotes | 1430 | 0.25 | Functional ≤ 10μM |
| NR1H4-2-E | Bile Acid Receptor FXR (cluster #2 Of 2), Eukaryotic | Eukaryotes | 0 | 0.00 | Functional ≤ 10μM |
| Z50418-4-O | Trypanosoma Brucei (cluster #4 Of 6), Other | Other | 4000 | 0.23 | Functional ≤ 10μM |
| Z50420-3-O | Trypanosoma Brucei Brucei (cluster #3 Of 7), Other | Other | 2200 | 0.24 | Functional ≤ 10μM |
| Z50466-5-O | Trypanosoma Cruzi (cluster #5 Of 8), Other | Other | 4000 | 0.23 | Functional ≤ 10μM |
| Z50472-2-O | Toxoplasma Gondii (cluster #2 Of 4), Other | Other | 1000 | 0.25 | Functional ≤ 10μM |
| Z50607-8-O | Human Immunodeficiency Virus 1 (cluster #8 Of 10), Other | Other | 1800 | 0.24 | Functional ≤ 10μM |
| Z80897-2-O | H9 (T-lymphoid Cells) (cluster #2 Of 2), Other | Other | 4400 | 0.23 | ADME/T ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| PA2GD_HUMAN | Q9UNK4 | Group IID Secretory Phospholipase A2, Human | 2.5 | 0.36 | Binding ≤ 1μM |
| PA2GE_HUMAN | Q9NZK7 | Group IIE Secretory Phospholipase A2, Human | 2.5 | 0.36 | Binding ≤ 1μM |
| PA2GF_HUMAN | Q9BZM2 | Group IIF Secretory Phospholipase A2, Human | 2.5 | 0.36 | Binding ≤ 1μM |
| PA2GA_HUMAN | P14555 | Phospholipase A2 Group IIA, Human | 2.5 | 0.36 | Binding ≤ 1μM |
| DHI1_HUMAN | P28845 | 11-beta-hydroxysteroid Dehydrogenase 1, Human | 1900 | 0.24 | Binding ≤ 10μM |
| DPOLB_RAT | P06766 | DNA Polymerase Beta, Rat | 4800 | 0.23 | Binding ≤ 10μM |
| PYGM_RABIT | P00489 | Glycogen Phosphorylase, Muscle Form, Rabit | 9000 | 0.21 | Binding ≤ 10μM |
| PA2GD_HUMAN | Q9UNK4 | Group IID Secretory Phospholipase A2, Human | 2.5 | 0.36 | Binding ≤ 10μM |
| PA2GE_HUMAN | Q9NZK7 | Group IIE Secretory Phospholipase A2, Human | 2.5 | 0.36 | Binding ≤ 10μM |
| PA2GF_HUMAN | Q9BZM2 | Group IIF Secretory Phospholipase A2, Human | 2.5 | 0.36 | Binding ≤ 10μM |
| Q7T3S7_ECHCA | Q7T3S7 | Phospholipase A2, Echca | 2300 | 0.24 | Binding ≤ 10μM |
| PA2GA_HUMAN | P14555 | Phospholipase A2 Group IIA, Human | 2.5 | 0.36 | Binding ≤ 10μM |
| PA21B_NAJME | P00599 | Phospholipase A2 Isozyme DE-I, Najme | 2900 | 0.23 | Binding ≤ 10μM |
| PA2A_PROFL | P59264 | Phospholipase A2 Isozyme PLA-A, Profl | 2500 | 0.24 | Binding ≤ 10μM |
| PTN1_HUMAN | P18031 | Protein-tyrosine Phosphatase 1B, Human | 2500 | 0.24 | Binding ≤ 10μM |
| PTN2_HUMAN | P17706 | T-cell Protein-tyrosine Phosphatase, Human | 3330 | 0.23 | Binding ≤ 10μM |
| NR1H4_HUMAN | Q96RI1 | Bile Acid Receptor FXR, Human | 0.1 | 0.42 | Functional ≤ 10μM |
| GPBAR_HUMAN | Q8TDU6 | G-protein Coupled Bile Acid Receptor 1, Human | 1430 | 0.25 | Functional ≤ 10μM |
| Z50607 | Z50607 | Human Immunodeficiency Virus 1 | 1800 | 0.24 | Functional ≤ 10μM |
| Z50472 | Z50472 | Toxoplasma Gondii | 1000 | 0.25 | Functional ≤ 10μM |
| Z50418 | Z50418 | Trypanosoma Brucei | 4000 | 0.23 | Functional ≤ 10μM |
| Z50420 | Z50420 | Trypanosoma Brucei Brucei | 2200 | 0.24 | Functional ≤ 10μM |
| Z50466 | Z50466 | Trypanosoma Cruzi | 4000 | 0.23 | Functional ≤ 10μM |
| Z80897 | Z80897 | H9 (T-lymphoid Cells) | 4400 | 0.23 | ADME/T ≤ 10μM |
| Description | Species |
|---|---|
| Acyl chain remodelling of PC | |
| Acyl chain remodelling of PE | |
| Acyl chain remodelling of PG | |
| Acyl chain remodelling of PI | |
| Acyl chain remodelling of PS | |
| Base-free sugar-phosphate removal via the single-nucleotide replacement pathway | |
| Class A/1 (Rhodopsin-like receptors) | |
| Endogenous sterols | |
| G alpha (s) signalling events | |
| Glucocorticoid biosynthesis | |
| Growth hormone receptor signaling | |
| Integrin alphaIIb beta3 signaling | |
| PPARA activates gene expression | |
| Recycling of bile acids and salts | |
| Regulation of IFNA signaling | |
| Regulation of IFNG signaling | |
| Removal of DNA patch containing abasic residue | |
| Resolution of AP sites via the single-nucleotide replacement pathway | |
| Synthesis of bile acids and bile salts | |
| Synthesis of bile acids and bile salts via 27-hydroxycholesterol | |
| Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol | |
| Synthesis of PA |
